期刊文献+

治疗偏头痛新型药物佐米曲普坦 被引量:3

下载PDF
导出
摘要 综述了佐米曲普坦的药理作用,药代动力学,适应症,不良反应。
作者 冯文涛
出处 《中国药业》 CAS 2000年第8期62-63,共2页 China Pharmaceuticals
  • 相关文献

参考文献17

  • 1Silberstein SD. Advances in understanding the pathophysiology of headache. Neurology, 1992,42 (suppl2): 6
  • 2Lance JVV. Current concepts of migraine pathogenesis. Neurology,1993,43(suppl 3):sll
  • 3Martin GR,Dixon RM. Preclinical and clinical pharmacology of the novel antimigraine compound 311C90 [ abstract ]. Headache, 1995,35:291
  • 4Goadsby PJ,Edvisson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin(5-HT)- 1D receptor agonist 311 C90. Headache, 1994,34: 394
  • 5Dixon R,Warrander A. The clinical pharmacokinetics of zolmitriptan.Celphalagia, 1997,17 (suppl 18 ): s 15
  • 6Seaber E,On N,Dixon RM,et al. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan(311C90). Br J Clin Pharmcol,1997,43(6):579
  • 7Rapoport AM,Ramadan NM,Adelman JU,et al. Optimizing the dose of zolmitriptan(Zomig. 311C90)for the acute treatment of migraine-a multicenter,double - blind, placebo - controlled, dose range-finding study. Neurology, 1997,49(5): 1210
  • 8Solomon GD, Cady RK, Klapper JA,et al. Clinical efficacy and tolerability of 2.5mg zolmitriptan for the acute treatment of migraine.Neurology, 1997,49:1219
  • 9Lowy MT. 2.5mg 311C in the treatment of migraine:efficacy and safety. European Journal of Neurology,1996,3(5): 152
  • 10Earl E. Clinical safety of 311C90:aggregated data from patients and volunteers to date. European Neurology,1995,36(2):8

同被引文献25

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部